

Technical Report No. 55

Detection and Mitigation of
2,4,6-Tribromoanisole and
2,4,6-Trichloroanisole Taints and
Odors in the Pharmaceutical and
Consumer Healthcare Industries

2012



PDA Task Force on Detection and Mitigation of 2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole Taints and Odors in the Pharmaceutical and Consumer Healthcare Industries

Authors

Anil Sawant, Ph.D. (Chair), Johnson & Johnson Consumer Companies, Inc.

William Callahan, Ph.D., Depomed

John Clark, M.D., MSPH, Risk Benefits LLC

Anthony M. Cundell, Ph.D., Merck & Co., Inc.

Jonine Greyling, Ph.D., Johnson & Johnson Consumer Products Company

Robert Johnson, RAJ Associates

Douglas Knawby, Ph.D., Johnson & Johnson Consumer Products Company

Janet Lim, M.D., Johnson & Johnson Consumer Companies, Inc.

Wendy Luo, Ph.D., Bristol-Myers Squibb Company

William J. Powers, Jr., Ph.D., Johnson & Johnson Consumer Companies, Inc.

Megan Sewell, Merck & Co., Inc.

Edward J. Smith, Ph.D., Packaging Science Resources, LLC

Katherine A. Stetson, GlaxoSmithKline LLC

Dirk E. Stevens, Ph.D., Covidien Pharmaceuticals

James Strickland, Pfizer, Inc.

Eric Thostesen, Janssen Pharmaceutical Company

Annalisa Torrente, (Project Manager)*, Johnson & Johnson Consumer Companies, Inc.

David A. Ulrich, Abbott Laboratories

Christine Vietri, AstraZeneca Pharmaceuticals LP

Gary E. Wilson, West Pharmaceuticals Services, Inc.

Contributors

William Beierschmitt, Ph.D., Pfizer, Inc.

Michael Fairbanks, Perrigo

Rachael Humphreys, Mylan

Nirdosh Jagota, Ph.D., Genentech,
a Member of the Roche Group

Richard V. Levy, Ph.D., Parenteral Drug Association

Gustavo S. Rodriguez, Rexam Healthcare

Doug Ross, M.D., Pfizer, Inc.

Sarah Sellers, PharmD, MPH, Q-Vigilance LLC

* PDA and the Task Force want to thank Annalisa Torrente for spending a considerable amount of time volunteering as the project manager for this Technical Report.

Detection and Mitigation of 2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole Taints and Odors in the Pharmaceutical and Consumer Healthcare Industries

Technical Report No. 55

ISBN: 978-0-939459-39-1

© 2012 Parenteral Drug Association, Inc.

All rights reserved.



EXECUTIVE SUMMARY

Since December 2009, there have been multiple recalls of pharmaceutical and over the counter drug products by at least five companies for musty, moldy odor caused by trace levels of 2,4,6-Tribromoanisole (TBA) taints. Based on literature review, a bench marking survey and data made available to the PDA Task Force it was concluded that the taint was caused by trace contamination of High Density Polyethylene packaging containers with highly volatile and odorous TBA during transportation and storage on wood pallets constructed in Puerto Rico from 2,4,6-Tribromophenol (TBP)-treated lumber from South America. The moisture content of the wood was sufficient to promote fungal growth resulting in the biomethylation of the halophenol to its haloanisole.

The trace concentrations found in customer complaint samples, i.e., ppb-ppt levels, require matrix-specific sampling, pre-concentration, and gas chromatography-mass spectrometry/olfactory detection that is only suitable for analytical confirmation of taints and not routine monitoring.

Possible risk mitigation steps identified by the Task Force include not constructing pallets from TBP treated lumber, controlling the moisture content of wood to levels not conducive to fungal growth, improved supply chain awareness of haloanisole taints, other sources of halophenols and adequate environmental control and ventilation in warehouses and during transportation.

Toxicological and safety studies conducted on TBA demonstrated no mutagenicity or systemic toxicology in rodents when dosed for up to 28 days at levels a billion-fold higher than potential human exposure from the recalled product. TBA dosing produced no diarrhea or any macroscopic or microscopic pathological effects along the GI tract in rat toxicity studies. Although nausea was reported by consumers sensing the musty, moldy odor, adverse event analysis by multiple recalling companies have not established a causal relationship between TBA and gastrointestinal events. Therefore, reactions of disgust to TBA taints appears to be sensory and/or behavioral and not toxicological and therefore is not a safety risk.

Based on the high margin of safety demonstrated in toxicity studies, there is no meaningful analytical threshold that can be based on toxicity. It is therefore necessary for individual companies to consider how the odor is being perceived by their customers and the likelihood that perception to the odor could impact patient therapy, i.e. the concern is that the musty, moldy odor from these taints could increase the likelihood that patients will not take their medication.

Table of Contents

1.0 INTRODUCTION	1	6.4 Laboratory Controls	29
1.1 Scope and Purpose.....	1	6.5 Environmental Monitoring	34
1.2 Overview of the Uses of Halophenols 2,4,6-Tribromophenol (TBP) and 2,4,6-Trichlorophenol (TCP) in Industry.....	1	6.6 Sensory Panel Examination of Material for Off-Odors	35
1.3 Fungal Biomethylation of 2,4,6-Tribromophenol (TBP) and 2,4,6-Trichlorophenol (TCP) To Generate 2,4,6-Tribromoanisole (TBA) and 2,4,6-Trichloroanisole (TCA)	2	6.7 Moisture Content of Wood	37
1.4 Sensory and Physiochemical Properties of 2,4,6-Tribromophenol (TBP), 2,4,6-Trichlorophenol (TCP), 2,4,6-Tribromoanisole (TBA), 2,4,6-Trichloroanisole (TCA), and Related Compounds	4	7.0 PRODUCT QUALITY COMPLAINTS, ADVERSE EVENTS, NOTIFICATION TO REGULATORY AGENCY, AND RECALL PROCEDURES	39
1.5 Migration and Diffusion of 2,4,6-Tribromophenol (TBP), 2,4,6-Trichlorophenol (TCP), 2,4,6-Tribromoanisole (TBA), and 2,4,6-Trichloroanisole (TCA)	6	7.1 Product Quality Complaints	39
1.6 Quality and Risk Management.....	6	7.1.1 TBA Signal Identification and Verification (Complaint Data).....	40
2.0 GLOSSARY OF TERMS	7	7.1.2 Complaint Investigation	40
3.0 PRINCIPLES AND TOOLS	13	7.1.3 Root Cause Analysis.....	40
3.1 The Supply Chain.....	13	7.2 Adverse Events (AEs).....	41
3.2 Good Distribution Practices (GDPs)	14	7.3 Notification to Regulatory Agency	41
3.3 Quality Risk Management	14	7.4 Recalls.....	41
4.0 INDUSTRY BENCHMARKING	15	8.0 TOXICOLOGY AND SAFETY	42
4.1 Industry Examples of Encounters in Supply Chain That Resulted in Product Tainting	15	8.1 Introduction and Background.....	42
4.2 TBA and TCA Taint Examples from Food and Beverage Industries.....	15	8.2 Literature Review on TBA.....	42
4.3 TBA and TCA Taint Examples from Pharmaceutical and Consumer Healthcare Industries	17	8.3 Toxicity of Haloanisoles and Halophenols	43
4.4 PDA TBA Industry Benchmarking Survey	20	8.3.1 TCP	43
5.0 DISTRIBUTION FLOW	21	8.3.2 TBP	44
5.1 Pallets.....	22	8.4 Data Generated on TBA.....	45
5.2 Shipping Containers	24	8.4.1 Non-Clinical (Toxicology)	45
5.3 Corrugate	25	8.4.2 Bacterial Reverse Mutation Assay (Ames). 45	
5.4 Plastics	26	8.4.3 Single-Dose Oral Rat Study.....	45
6.0 ANALYTICAL	27	8.4.4 5-Day Repeat-Dose Oral Rat Study	46
6.1 Overview	27	8.4.5 28-Day Repeat-Dose Oral Rat Study	46
6.2 Method Review	27	8.4.6 TBA Exposure in Rats	46
6.3 Method Acceptance Criteria (for Haloanisole and Halophenol Concentrations).....	28	8.5 Discussion.....	47
		8.5.1 TBA Theoretical Thresholds.....	47
		8.6 Results/Conclusions	49
		9.0 QUALITY RISK MANAGEMENT	50
		9.1 Risk Assessment.....	51
		9.1.1 Risk Identification	51
		9.1.2 Risk Analysis	53
		9.1.3 Risk Evaluation	53
		9.2 Risk Control.....	53
		9.2.1 Risk Reduction.....	53
		9.2.1.1 In Pallet.....	54
		9.2.1.2 In Warehouse	54
		9.2.1.3 In Shipping	54
		9.2.1.4 In Customer Complaints	54
		9.2.2 Risk Acceptance.....	54

9.3 Risk Review.....	55	11.4.1 Pallet Manufacturers.....	66
10.0 CONCLUSION	56	11.4.2 Shipping/Transportation.....	67
11.0 APPENDIX.....	58	11.4.3 Storage, Warehousing, Distribution	68
11.1 Supplemental Pallet and Shipping Container Information	58	11.4.4 Pharmaceutical and Consumer Healthcare Manufacturing	68
11.1.1 Best Practices	58	11.5 Sample SOP on Pallet Control Procedures..	68
11.1.2 Transport and Distribution.....	60	11.6 Shipping Container Flow Chart.....	72
11.1.3 Storage throughout the Supply Chain ...	61	12.0 ACRONYMS.....	73
11.1.4 Pharmaceutical and Consumer Healthcare Manufacturers	61	12.1 Regulatory Authorities	73
11.2 Pallet Suppliers and Oversight of Suppliers	62	12.2 Technical Groups	73
11.3 Auditing/ Risk Assessment of Wood Pallets and Shipping Containers	64	12.3 Technical Terms	73
11.4 Supply Chain Quality Risk Management ...	65	13.0 ADDITIONAL READING MATERIAL	74
		14.0 REFERENCES.....	76

FIGURES AND TABLES INDEX

Figure 1.3-1	Halophenol to Haloanisole Biomethylation Conversions	2	Table 6.3-2	“Parts per” Notations.....	29
Table 1.3-1	Representative Reports in the Literature on the Biomethylation of Halophenols ..	3	Figure 6.4-1	Example Mass Spectra for TCA and TBA	31
Table 1.3-2	Equilibrium Moisture Content of Wood at Different Temperatures and Humidity Related to Fungal Growth	4	Table 6.4-1	Reference Standard Limit of Detection by Method.....	33
Table 1.4-1	Sensory Characteristics of Selected Organohalogen.....	5	Table 6.4-2	Approximate Sample Limit of Detection by Matrix Type by Method Type	33
Table 1.4-2	Physicochemical Attributes of Organohalogen of Interest.....	5	Table 6.4-3	Typical Sample Preparation Approaches by Matrix	34
Figure 3.1-1	The Pharmaceutical and Consumer Healthcare Supply Chain.....	13	Table 8.3.1-1	TCP and TCA Exposure Levels	44
Table 4.1-1	Representative Literature References to Organohalogen Taints in the Food, Beverage, Consumer Healthcare, Pharmaceutical Industries	15	Table 8.5-1	TBA versus Theoretical Threshold Levels	48
Table 4.2-1	Concentration of Organohalogen in Beer and Packaging Materials	16	Figure 9.0-1	Quality Risk Management Process for Haloanisole Taints.....	50
Table 4.3-1	Examples of TBA and TCA Taint Cases from Pharmaceutical and Consumer Healthcare Industries.....	18	Table 9.1.1-1	Risk Identification	51
Table 6.3-1	Concentration-Dependent Pharmaceutical Guidances	29	Table 11.4.1-1	Quality Risk Management for Pallet Manufacturers	66
			Table 11.4.2-1	Quality Risk Management for Shipping/Transportation.....	67
			Table 11.4.3-1	Quality Risk Management for Storage, Warehousing, Distribution	68
			Table 11.4.4-1	Additional Risks to Manufacturers	68
			Figure 11.6-1	Shipping Container Flow Chart	72

1.0 Introduction

1.1 Scope and Purpose

The scope of this technical report covers 2,4,6-tribromoanisole (TBA) and 2,4,6-trichloroanisole (TCA) taints and odors. These particular musty, moldy taints have very low thresholds of detection, at parts per trillion (ppt), and high volatility relative to other organohalogen taints. Taints arise from an external source as opposed to off-odors or off-flavors from internal changes to a product (i.e., microbial spoilage).

The purpose of this report is to provide guidance on how to detect and mitigate TBA and TCA odors and taints. Well recognized in the food and beverage industries (1–4), the literature features knowledge from these industries regarding the origin of these odors and taints, analytical methods developed, and risk management strategies employed. In 2009, this became an issue for the pharmaceutical and consumer healthcare industries with product recalls from four companies due to the risk of product exposure to the TBA taint from tribromophenol-treated wood pallets. Recalls from additional firms continued through 2011.

This report will provide background on issues with TBA and TCA taints, highlighting:

- Uses of 2,4,6-tribromophenol (TBP) and 2,4,6-trichlorophenol (TCP) in industry
- Role of fungal halophenol methylation that generates TBA and TCA haloanisole taints
- Sensory and physiochemical properties of TBP, TCP, TBA and TCA
- Case examples from food and beverage industries with root causes and remedial actions
- Recent examples of TBA taint recalls from the pharmaceutical and consumer healthcare industries

Additionally, this report will provide guidance on signal detection from adverse event and/or product quality complaints and resulting recalls, toxicology and safety, analytical method development and use, supply chain controls, risk analysis and mitigation. Definitions of technical terms used in this report can be found in the glossary. The principles and tools used to manage these taints are also defined in this report.

1.2 Overview of the Uses of Halophenols 2,4,6-Tribromophenol (TBP) and 2,4,6-Trichlorophenol (TCP) in Industry

Multiple examples from the literature of the food and beverage industry indicate that TBP and TCP, precursors to the TBA and TCA taints, can enter the supply chain from various sources and can also form in the environment under certain conditions. Examples of these sources are highlighted below.

TBP is used as a wood preservative in various parts of the world. Although not registered for use in the United States and the European Union, TBP is known to have been used as a wood preservative in Central America, South America, Eastern Europe and Northern Asia, according to the literature (2, 5). Additionally, TBP is known to be used as fire-retardant agents in insulation (e.g., walls, ceiling tiles), epoxy resins (e.g., floor sealants), polyurethanes, plastics, paper and textiles (5). TBP has also been used in pesticides, antiseptic agents and detergents (6). It is also known that naturally occurring phenol residues in water and wood materials can be halogenated in the presence of bromine under certain conditions to form TBP (7).

According to the 2005 Concise International Chemical Assessment Document No. 66 (8), TBP is reacted with sodium hydroxide to form the sodium salt of tribromophenol in water, which is used as a wood preservative. Standard application methods of pressure and vacuum impregnation, dipping, brushing, and spraying of the wood are used. The solution is very effective in controlling insects, fungi, and bacte-